Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11462599 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11454110 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11471767 | 0.81 | LMNA (0.67) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11151054 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL10962832 | 0.79 | ADORA2A (0.68) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11452052 | 0.79 | HTT (0.67) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11459985 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL11017499 | 0.76 | PDE4A (0.65) | SMN1; SMN2LMNACYP1A2CYP2D6MAPK1 | |
| SCHEMBL11454107 | 0.75 | HTT (0.60) | SMN1; SMN2LMNAALDH1A1NPSR1POLB | |
| SCHEMBL10442061 | 0.73 | CYP1A2 (0.61) | SMN1; SMN2LMNACYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948182-B1 | METHOD FOR TREATING NEURONAL AND NON-NEURONAL PAIN | ZHUO MIN (CA) | 2012-12-12 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20090233922-A1 | Method for Treating Neuronal and Non-Neuronal Pain | FOREVER CHEER INTERNATIONAL LIMITED (HK) | 2009-09-17 | — | — | US | disclosed |
| US-20090233922-A1 | Method for Treating Neuronal and Non-Neuronal Pain | FOREVER CHEER INTERNATIONAL LIMITED (HK) | 2009-09-17 | — | — | US | disclosed |
| WO-2007041863-A1 | METHOD FOR TREATING NEURONAL AND NON-NEURONAL PAIN | ZHUO MIN (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-4189485-A | ANTICOCCIDIAL ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | SMN1; SMN2 3821/4885LMNA 4838/4885ALDH1A1 3995/4885 |
| US-20090233922-A1 | Method for Treating Neuronal and Non-Neuronal Pain | OPRL1, ADCY1, GRIN1 | SMN1; SMN2 197/4885LMNA 2735/4885ALDH1A1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.